Literature DB >> 9097923

Analysis of T cell activation pathways in patients with liver cirrhosis, impaired delayed hypersensitivity and other T cell-dependent functions.

C A Schirren1, M C Jung, R Zachoval, H Diepolder, R Hoffmann, G Riethmüller, G R Pape.   

Abstract

Patients with cirrhosis of the liver frequently demonstrate anergy in intracutaneous tests and fail to respond to vaccination, suggesting impaired delayed hypersensitivity and other T cell-dependent functions in vivo. T cell activation through the coordinated interaction of different cells of the immune system (B cell, antigen-presenting cells (APC)) is an important step in the induction of cellular and humoral immune responses. Impaired T cell-dependent functions in patients with liver cirrhosis may thus be explained by defective T cell activation. We prospectively investigated T cell activation pathways in 12 patients (nine males, three females) with alcoholic liver cirrhosis (seven Child Pugh stage A and B (CP A + B), five Child Pugh stage C (CP C)) and five healthy controls and compared the in vitro results of T cell activation with data obtained in vivo, e.g. intracutaneous tests and vaccination against hepatitis B surface antigen (HBs-Ag). Five out of eight patients who completed vaccination against hepatitis B virus infection were non-responders; one of the three responders had a non-protective anti-HBs titre. Moreover, three of five patients with alcoholic liver cirrhosis CP A + B, and two out of three with CP C were anergic in intracutaneous tests to a set of diverse antigens. All parameters of T cell activation were normal, including proliferation mediated by CD2, CD3-T cell receptor (TCR) complex, and CD28; acquisition of responsiveness to exogenous IL-2 and IL-4; activation of proteinkinase C (PKC) by phorbol ester and calcium influx by addition of ionomycin. The ability of monocytes to deliver costimulatory signals was preserved in patients with alcoholic cirrhosis. In addition, serum of patients with alcoholic liver disease did not inhibit T cell proliferation. We conclude that, although in patients with alcoholic liver cirrhosis T cell-dependent functions are impaired in vivo, T cell activation pathways are not responsible for the observed immune defect.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9097923      PMCID: PMC1904621          DOI: 10.1046/j.1365-2249.1997.d01-985.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  7 in total

Review 1.  Spontaneous bacterial peritonitis: The clinical challenge of a leaky gut and a cirrhotic liver.

Authors:  Philipp Lutz; Hans Dieter Nischalke; Christian P Strassburg; Ulrich Spengler
Journal:  World J Hepatol       Date:  2015-03-27

Review 2.  Antitubercular therapy in patients with cirrhosis: challenges and options.

Authors:  Naveen Kumar; Chandan Kumar Kedarisetty; Sachin Kumar; Vikas Khillan; Shiv Kumar Sarin
Journal:  World J Gastroenterol       Date:  2014-05-21       Impact factor: 5.742

Review 3.  Risk factors and outcome of bacterial infections in cirrhosis.

Authors:  Tony Bruns; Henning W Zimmermann; Andreas Stallmach
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

4.  Lymphocyte subsets in alcoholic liver disease.

Authors:  Luís Costa Matos; Paulo Batista; Nuno Monteiro; João Ribeiro; Maria A Cipriano; Pedro Henriques; Fernando Girão; Armando Carvalho
Journal:  World J Hepatol       Date:  2013-02-27

5.  Donor-derived regulatory dendritic cell infusion results in host cell cross-dressing and T cell subset changes in prospective living donor liver transplant recipients.

Authors:  Camila Macedo; Lillian M Tran; Alan F Zahorchak; Helong Dai; Xinyan Gu; Ranjithkumar Ravichandran; Thalachallour Mohanakumar; Beth Elinoff; Adriana Zeevi; Mindi A Styn; Abhinav Humar; Fadi G Lakkis; Diana M Metes; Angus W Thomson
Journal:  Am J Transplant       Date:  2020-12-23       Impact factor: 9.369

6.  Prognostic impact of peritonitis in hemodialysis patients: A national-wide longitudinal study in Taiwan.

Authors:  Yueh-An Lu; Kun-Hua Tu; Cheng-Chia Lee; Patricia W Wu; Chee-Jen Chang; Ya-Chung Tian; Chih-Wei Yang; Pao-Hsien Chu
Journal:  PLoS One       Date:  2017-03-16       Impact factor: 3.240

7.  Poor Response to Inactivated SARS-CoV-2 Vaccine in Patients With Chronic Liver Disease.

Authors:  Huanhuan Cao; Rong Fan
Journal:  Clin Gastroenterol Hepatol       Date:  2022-02-03       Impact factor: 13.576

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.